Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.
Carmi Levy I, Amitzi L, Lavi E, Zilony - Hanin N, Pode Z, Berger R, Smith K. Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors. Journal Of Clinical Oncology 2024, 42: tps2692-tps2692. DOI: 10.1200/jco.2024.42.16_suppl.tps2692.Peer-Reviewed Original ResearchSolid tumorsIndividualized immunotherapyClinical benefitTumor cellsFirst-in-human phase 1Preliminary evidence of clinical benefitEvidence of clinical benefitImmune-oncology agentsDose-escalation partAdvanced solid tumorsDose-escalation studyRelapsed/refractory solid tumorsAdvanced/metastatic solid tumorsTumor cell lysisPatient tumor cellsPhase 1 studyImmune T cellsAntigen presenting cellsFirst-in-humanStimulate antigen presenting cellsIdentification of biomarkersCTCAE v5Dose expansionIT injectionSystemic therapy